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Background
Schistosomiasis remains a severe problem of public health
in developing countries [1]. Several reports show that pra-
ziquantel, the drug of choice for treating schistosomiasis,
can select Schistosoma mansoni strains resistant to the
drug. Thus, developing new drugs against this parasitosis
is a highly desirable goal [2]. In this context, enzymes
involved in energetic metabolism could represent attrac-
tive drug targets for novel anti-schistosome chemothera-
pies [3,4]. We report a chemogenomic strategy for
identification of approved drugs that may be able to inter-
fere with energetic metabolism of the Schistosoma
mansoni.
Methods
The chemogenomic study was performed on a list con-
taining 734 genes involved in oxidative phosphorylation
(n = 45); nitrogen metabolism (n = 642); glycolysis (n = 11);
citrate cycle (n = 10); and others (n = 26). Next, it was
obtained from the GeneDB S. mansoni genome database
individual information for genes (amino acid sequence in
FASTA format, product name, and biological process).
Each of these protein sequences was treated as a potential
drug target and used to screen three freely available data-
bases (DrugBank, STITCH 3.1, and TTD) based in the
concept of the target sequence similarity. The targets with
E-value score ≤ 10-5 and score ≥ 0.7 were considered for
further analyses.
Results and conclusions
We were able to identify several drugs that are expected to
interact with 6 targets involved in nitrogen metabolism
(carbonic anhydrase II and carbonic anidrase), citrate cycle
(succinate dehydrogenase), oxidative phosphorylation
(ATP synthase delta chain and NADH-ubiquinone oxidor-
eductase mitochondrial precursor), and glutamate metabo-
lism (glutaminase). One of these targets was associated
with thiabendazole, whose activity has been previously
evaluated against S. mansoni. [5]. However, 18 drugs were
predicted to have activity against other targets and have
never been evaluated against schistosoma parasites
(e.g., acetazolamide, doxorubicin, morantel tartrate,
axantel pamoate, thiabendazole, and menthol). Our next
step is to experimentally screen these drugs against
S. mansoni. Being a cost and time saving route, drug repo-
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